A recent study suggests that individuals who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional lifestyle programs.
Findings released in a prominent medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications must be aware of the risk of rapid weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about 18 months.
Comparing Approaches
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with conventional dieting.
Researchers point out that people who lose weight through dieting generally experience a slower creep back—around 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Nutrition scientists suggest the mechanism of the drugs explains the heightened regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating far more likely."
An Ongoing Issue?
Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, considering the significant potential of relapse, the therapy is often life-long.
This perspective is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent nature of excess weight," comparing it to managing diseases like hypertension.
Patient Experiences
People who have stopped the jabs explain a powerful return of hunger.
"It felt as if a switch that goes on and you're instantly extremely hungry," recalled a patient.
This challenge is worsened if patients have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Interest
Survey data show that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on ongoing lifestyle management.
